PDF(Pubmed)
Abstract：
Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.
摘要：
对特应性疾病的分子机制的不断了解使生物制剂的开发能够精确地靶向这些疾病。食物过敏（FA）和嗜酸性胃肠道疾病（EGID）是由相似的炎症分子机制驱动的，并且存在于相同的特应性疾病谱中。因此,正在研究许多相同的生物制剂，以针对不同疾病状态共有机制的关键驱动因素。生物制剂用于治疗FA和EGIDs的巨大潜力突出显示，正在进行的临床试验（超过30项）的数量显着增加，评估其在这些疾病状态中的使用。以及最近美国食品和药物管理局批准dupilumab用于治疗嗜酸性粒细胞性食管炎。在这里，我们讨论了过去和现在在FA和EGIDs中使用生物制剂的研究，以及它们在未来改善治疗方案中的潜在作用。需要在临床上广泛使用生物制剂。
